A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

Records show that a top U.S. regulator rejected the recommendations of agency experts and limited the use of Covid vaccines.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Cobenfy: A Key Growth Driver One of the most significant developments for Bristol-Myers Squibb has been the launch and performance of Cobenfy, its new drug for schizophrenia.

After decades of antipsychotic drugs, a new FDA-approved treatment for schizophrenia targets a different brain system—with ...

In September 2024, the FDA approved Cobenfy, an oral medication for schizophrenia in adults. Data from the EMERGENT clinical program supported the FDA approval of Cobenfy.